{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:42:31Z","timestamp":1768707751693,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["slas-discovery.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SLAS Discovery"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.slasd.2023.01.001","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T21:24:12Z","timestamp":1673645052000},"page":"95-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["High throughput screening for drugs that inhibit 3C-like protease in SARS-CoV-2"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9217-6892","authenticated-orcid":false,"given":"Emery","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith E.","family":"Davis-Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben D.","family":"Garcia-Ordonez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tu-Trinh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Hull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7169-8192","authenticated-orcid":false,"given":"Emily","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuerong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0683-8886","authenticated-orcid":false,"given":"Thomas D.","family":"Bannister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4431-1372","authenticated-orcid":false,"given":"Pierre","family":"Baillargeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7734-0105","authenticated-orcid":false,"given":"Louis","family":"Scampavia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Farzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9080-4226","authenticated-orcid":false,"given":"Timothy P.","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.slasd.2023.01.001_bib0001","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.slasd.2023.01.001_bib0002","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds","volume":"115","author":"Baez-Santos","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.slasd.2023.01.001_bib0003","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.slasd.2023.01.001_bib0004","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/2472555220963667","article-title":"High-throughput screening for drugs that inhibit papain-like protease in SARS-CoV-2","volume":"25","author":"Smith","year":"2020","journal-title":"SLAS Discov"},{"key":"10.1016\/j.slasd.2023.01.001_bib0005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.slasd.2023.01.001_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.616341","article-title":"Recent progress in the drug development targeting SARS-CoV-2 main protease as treatment for COVID-19","volume":"7","author":"Cui","year":"2020","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.slasd.2023.01.001_bib0007","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.slasd.2023.01.001_bib0008","doi-asserted-by":"crossref","first-page":"e00784","DOI":"10.1128\/mbio.00784-22","article-title":"Gain-of-signal assays for probing inhibition of SARS-CoV-2 Mpro\/3CLproin living cells","volume":"13","author":"Moghadasi","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.slasd.2023.01.001_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105183","article-title":"A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition","volume":"195","author":"Dey-Rao","year":"2021","journal-title":"Antiviral Res"},{"key":"10.1016\/j.slasd.2023.01.001_bib0010","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/v13020173","article-title":"Development of a cell-based luciferase complementation assay for identification of SARS-CoV-2 3CLpro inhibitors","volume":"13","author":"Rawson","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.slasd.2023.01.001_bib0011","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12033-021-00299-7","article-title":"Cell-based high-throughput screening protocol for discovering antiviral inhibitors against SARS-COV-2 main protease (3CLpro)","volume":"63","author":"Rothan","year":"2021","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.slasd.2023.01.001_bib0012","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis","volume":"54","author":"Wen","year":"2022","journal-title":"Ann Med"},{"key":"10.1016\/j.slasd.2023.01.001_bib0013","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/1087057114563494","article-title":"CHO-S antibody titers >1 gram\/liter using flow electroporation-mediated transient gene expression followed by rapid migration to high-yield stable cell lines","volume":"20","author":"Steger","year":"2015","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.slasd.2023.01.001_bib0014","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/jm401712t","article-title":"X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of h\u00b5Man coronavirus papain-like proteases","volume":"57","author":"Baez-Santos","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.slasd.2023.01.001_bib0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.slasd.2023.01.001_bib0016","doi-asserted-by":"crossref","first-page":"10750","DOI":"10.1073\/pnas.1810137115","article-title":"The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis","volume":"115","author":"Janes","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.slasd.2023.01.001_bib0017","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1038\/s41467-020-18233-x","article-title":"Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease","volume":"11","author":"Fu","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.slasd.2023.01.001_bib0018","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1021\/acsptsci.0c00130","article-title":"Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors","volume":"3","author":"Ma","year":"2020","journal-title":"ACS Pharmacol Transl Sci"}],"container-title":["SLAS Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555223000011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555223000011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T11:55:48Z","timestamp":1762862148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2472555223000011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2472555223000011"],"URL":"https:\/\/doi.org\/10.1016\/j.slasd.2023.01.001","relation":{},"ISSN":["2472-5552"],"issn-type":[{"value":"2472-5552","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High throughput screening for drugs that inhibit 3C-like protease in SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"SLAS Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.slasd.2023.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of Society for Laboratory Automation and Screening.","name":"copyright","label":"Copyright"}]}}